Knight Therapeutics Inc. (TSX: GUD)

Canada flag Canada · Delayed Price · Currency is CAD
5.86
+0.14 (2.45%)
Jul 15, 2024, 4:00 PM EDT
20.08%
Market Cap 593.78M
Revenue (ttm) 332.21M
Net Income (ttm) -17.44M
Shares Out 101.33M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39,180
Open 5.72
Previous Close 5.72
Day's Range n/a
52-Week Range 4.35 - 6.22
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 8, 2024

About Knight Therapeutics

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Ne... [Read more]

Sector Healthcare
CEO Ms. Samira Sakhia BCom, CA, CPA, MBA
Employees 725
Stock Exchange Toronto Stock Exchange
Ticker Symbol GUD
Full Company Profile

Financial Performance

In 2023, GUD's revenue was 328.20 million, an increase of 11.80% compared to the previous year's 293.56 million. Losses were -16.84 million, -43.68% less than in 2022.

Financial Statements

News

Knight Therapeutics reports Q1 results

2 months ago - Seeking Alpha

Knight Therapeutics Reports First Quarter 2024 Results

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial re...

2 months ago - GlobeNewsWire

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusi...

2 months ago - GlobeNewsWire

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the votin...

2 months ago - GlobeNewsWire

Notice of Knight Therapeutics’ First Quarter 2024 Results Conference Call

MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financia...

2 months ago - Financial Post

Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call

MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financi...

2 months ago - GlobeNewsWire

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...

4 months ago - GlobeNewsWire

Notice of Knight Therapeutics’ Fourth Quarter and Year End 2023 Results Conference Call

MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year e...

4 months ago - Financial Post

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year ...

4 months ago - GlobeNewsWire

Knight Therapeutics Inc. Celebrates its First Decade of Success

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year ann...

4 months ago - GlobeNewsWire

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit...

5 months ago - GlobeNewsWire

Knight Therapeutics Announces Launch of Bijuva® in Canada

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol ...

5 months ago - GlobeNewsWire

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada....

6 months ago - GlobeNewsWire

Knight Therapeutics Inc. (KHTRF) Q3 2023 Earnings Call Transcript

Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ETCompany ParticipantsSamira Sakhia - President and Chief...

8 months ago - Seeking Alpha

Knight Therapeutics reports Q3 results

Knight Therapeutics reports Q3 earnings, with non-GAAP EPS of C$0.15 and revenue of C$0.08M.

8 months ago - Seeking Alpha

Knight Therapeutics Reports Third Quarter 2023 Results

MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...

8 months ago - GlobeNewsWire

Notice of Knight Therapeutics’ Third Quarter 2023 Results Conference Call

MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financi...

9 months ago - Financial Post

Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call

MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financ...

9 months ago - GlobeNewsWire

Knight Therapeutics Inc. places No. 90 on The Globe and Mail’s fifth-annual ranking of Canada’s Top Growing Companies

MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top...

10 months ago - Financial Post

Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies

MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada's To...

10 months ago - GlobeNewsWire

Knight Therapeutics Reports Second Quarter 2023 Results

MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...

1 year ago - GlobeNewsWire